Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

Ginkgo Bioworks (NYSE: DNA) has announced a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock deal valued at approximately $300 million. Zymergen stockholders will receive 0.9179 Ginkgo shares per Zymergen share, resulting in a pro forma ownership of 5.25% in the combined entity. This acquisition aims to enhance Ginkgo's horizontal synthetic biology platform through Zymergen's technology and assets, fostering new growth opportunities. The transaction is expected to close by Q1 2023, pending regulatory and stockholder approvals.

Ginkgo Bioworks (NYSE: DNA) has signed a definitive agreement to acquire Bayer's 175,000-square-foot Biologics R&D center for approximately $83 million. This acquisition aims to enhance Ginkgo's agricultural biologicals capabilities. The deal is expected to close in Q4 2022, pending regulatory approvals. Additionally, Ginkgo will enter a three-year collaboration with Bayer, focusing on advancing various agricultural biological programs, including nitrogen fixation. This partnership is anticipated to generate royalty earnings from products developed under the collaboration, potentially offsetting operational costs.

Ginkgo Bioworks (NYSE: DNA) announced a new cell programming project in collaboration with Sumitomo Chemical Co., Ltd. This partnership focuses on producing sustainable, animal-free molecules for the personal care and cosmetic industries. Leveraging Ginkgo's expertise and extensive codebase, the project aims to enhance sustainability while offering competitive advantages in the market. Sumitomo Chemical recognizes the potential of synthetic biology in meeting the growing demand for eco-friendly products. This initiative complements their ongoing collaboration, initiated in 2021, aimed at bio-based production across multiple sectors.

Cronos Group (NASDAQ: CRON) and Ginkgo Bioworks (NYSE: DNA) have achieved a productivity milestone in their collaboration to produce cultured cannabinoids, specifically tetrahydrocannabivarin (THCV). This development is part of an initiative launched in 2018 aimed at creating rare cannabinoids at industrial scale. Cronos has issued approximately 2.2 million common shares to Ginkgo as a result of this achievement. The partnership underscores both companies' commitment to innovation in the cannabis industry, enhancing Cronos' product pipeline with potential market introductions for THCV.

Ginkgo Bioworks (NYSE: DNA) will participate in Goldman Sachs' 43rd Annual Global Healthcare Conference on June 15, 2022, at 10:40 a.m. PT. The company focuses on cell programming, providing a platform for biotechnology applications across various sectors including pharmaceuticals and agriculture. Ginkgo has also supported COVID-19 efforts such as pooled testing and vaccine optimization. Further details, including a webcast link, will be available on their investor relations website.

On June 7, 2022, Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Novo Nordisk to develop novel expression hosts for pharmaceutical products targeting chronic diseases like diabetes and obesity. This partnership aims to enhance the discovery and development of biological medicines. Ginkgo will receive an upfront R&D fee and may earn milestone payments throughout the collaboration. This multi-year project underscores Ginkgo's commitment to leveraging synthetic biology for improved healthcare solutions.

On June 6, 2022, Ginkgo Bioworks (NYSE: DNA) announced the acquisition of assets from Bitome, a leader in real-time metabolite monitoring technology. This technology uses machine learning to enhance bioprocess optimization by providing continuous monitoring of cell culture media. The integration aims to streamline the development timelines of Ginkgo's cell programming platform, potentially accelerating product readiness. Ginkgo's co-founder highlighted that this acquisition will significantly improve strain testing at scale, addressing a critical bottleneck in synthetic biology.

Ginkgo Bioworks (NYSE: DNA) will participate in William Blair's 42nd Annual Growth Stock Conference on June 9, 2022, at 11:20 a.m. CT. The conference aims to showcase growth stocks to investors and provide insights into Ginkgo's cell programming platform, which serves various markets from agriculture to pharmaceuticals. Details about the event, including a webcast link and a replay, can be found on the company's investor relations website.